Low-resolution electromagnetic tomography and treatment response in obsessive-compulsive disorder

International Journal of Neuropsychopharmacology

Volumn 9, Issue 1, 2006, Pages 89-94

  Fontenelle, Leonardo F ^a,c   Mendlowicz, Mauro V ^b   Ribeiro, Pedro ^a   Piedade, Roberto A ^a   Versiani, Marcio ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^c NONE   (Brazil)

Author keywords

Antidepressants; LORETA; Obsessive compulsive disorder; Topographic brain mapping; Treatment outcome

Indexed keywords

ANTIDEPRESSANT AGENT; CLOMIPRAMINE; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ARTICLE; BRAIN MAPPING; BRAIN REGION; CINGULATE GYRUS; DRUG RESPONSE; ELECTRIC ACTIVITY; ELECTROENCEPHALOGRAM; ELECTROMAGNETIC FIELD; FEMALE; FRONTAL CORTEX; FRONTAL LOBE; HUMAN; LOW RESOLUTION ELECTROMAGNETIC TOMOGRAPHY; MALE; MAXIMUM TOLERATED DOSE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; STUDENT T TEST; TOMOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BETA RHYTHM; BRAIN MAPPING; ELECTROMAGNETICS; FEMALE; FRONTAL LOBE; GYRUS CINGULI; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; TOMOGRAPHY; TREATMENT OUTCOME;

EID: 30344473901     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145705005584     Document Type: Article

References (26)

1. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (4th edn). Washington, DC: American Psychiatric Association.
2. Beck AT (1978). Depression Inventory. Philadelphia: Philadelphia Center for Cognitive Therapy.
3. Breiter HC, Rauch SL, Kwong KK, Baker JR, Weisskoff RM, Kennedy DN, Kendrick AD, Davis TL, Jiang A, Cohen MS, et al. (1996) Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder. Archives of General Psychiatry 53, 595-606.
4. First MB, Spitzer RL, Gibbon M, Williams JBW (1997). Structured Clinical Interview for DSM-IV Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute.
5. Fontenelle LF, Marques C, Versiani M (2002). The effect of gender on the clinical features and therapeutic response in obsessive-compulsive disorder. Revista Brasileira de Psiquiatria 24, 7-11.
6. Friston KJ, Poline JB, Holmes AP, Price CJ, Frith, CD (1996). Detecting activation in PET and fMRI: levels of inference and power. Neuroimage 4, 223-235.
7. 15)O]-PET and LORETA during cognitive and pharmacological activation. Human Brain Mapping 22, 83-96.
8. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS, (1989). The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Archives of General Psychiatry 46, 1006-1011.
9. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education and Welfare Publication, ADM.
10. Hamilton M (1967). Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 6, 278-296.
11. Hollander E, Friedberg J, Wasserman S, Allen A, Birnbaum M, Koran LM (2003). Venlafaxine in treatment-resistant obsessive-compulsive disorder. Journal of Clinical Psychiatry 64, 546-550.
12. Karadag F, Oguzhanoglu NK, Kurt T, Oguzhanoglu A, Atesci F, Ozdel O (2003). Quantitative EEG analysis in obsessive compulsive disorder. International Journal of Neuroscience 113, 833-847.
13. Koran LM, Quirk T, Lorberbaum JP, Elliott M (2001). Mirtazapine treatment of obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 21, 537-539.
14. Mavissakalian M (2002). Comments on the pharmacological treatment of obsessive-compulsive disorder. In: Maj M, Sartorius N, Okasha A, Zohar J (Eds.), Obsessive-Compulsive Disorder (pp. 71-73). Chichester: John Wiley & Sons Ltd.
15. Mayberg HS, Brannan SK, Mahurin RK, Jerabek PA, Brickman JS, Tekell JL, et al. (1997). Cingulate function in depression: a potential predictor of treatment response. Neuroreport 8, 1057-1061.
16. Pascual-Marqui RD, Esslen M, Kochi K, Lehmann D (2002). Functional imaging with low-resolution brain electromagnetic tomography (LORETA): a review. Methods and Findings in Experimental and Clinical Pharmacology 24 (Suppl. C), 91-5.
17. Pizzagalli D, Pascual-Marqui RD, Nitschke JB, Oakes TR, Larson CL, Abercrombie HC, Schaefer SM, Koger JV, Benca RM, Davidson RJ (2001). Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. American Journal of Psychiatry 158, 405-415.
18. Rauch SL, Shin LM, Dougherty DD, Alpert NM, Fischman AJ, Jenike MA (2002). Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. Neuropsychopharmacology 27, 782-791.
19. Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, Baxter Jr. LR (2003). Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. American Journal of Psychiatry 160, 522-532.
20. Saxena S, Brody AL, Maidment KM, Dunkin JJ, Colgan M, Alborzian S, Phelps ME, Baxter Jr. LR (1999). Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 21, 683-693.
21. Swedo SE, Schapiro MB, Grady CL, Cheslow DL, Leonard HL, Kumar A, Friedland R, Rapoport SI, Rapoport JL (1989). Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Archives of General Psychiatry 46, 518-523.
22. Swedo SE, Pietrini P, Leonard HL, Schapiro MB, Rettew DC, Goldberger EL, Rapoport SI, Rapoport JL, Grady CL (1992). Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy. Archives of General Psychiatry 49, 690-694.
23. Tot S, Ozge A, Comelekoglu U, Yazici K, Bal N (2002). Association of QEEG findings with clinical characteristics of OCD: evidence of left frontotemporal dysfunction. Canadian Journal of Psychiatry 47, 538-545.
24. Ursu S, Stenger VA, Shear MK, Jones MR, Carter CS (2003). Overactive action monitoring in obsessive-compulsive disorder: evidence from functional magnetic resonance imaging. Psychological Science 14, 347-353.
25. Veiga H, Deslandes A, Cagy M, Fiszman A, Piedade RA, Ribeiro P (2003). Neurocortical electrical activity tomography in chronic schizophrenics. Arquivos de Neuropsiquiatria 61, 712-717.
26. Yücel M, Wood SJ, Fornito A, Riffkin J, Velakoulis D, Pantelis C (2003). Anterior cingulate dysfunction: implications for psychiatric disorders? Journal of Psychiatry and Neuroscience 28, 350-354.